After conducting a thorough search using the information provided, I was unable to find an exact date for Apotex's Ruxolitinib FDA submission. However, according to DrugPatentWatch.com [1], Ruxolitinib, which is a JAK1/JAK2 inhibitor, was approved by the FDA on November 16, 2011, for the treatment of myelofibrosis. Apotex, a Canadian pharmaceutical company, is one of the manufacturers of this drug.

It is important to note that the FDA approval date does not necessarily correspond to the date of submission. The FDA typically takes several months to review a new drug application, and the review process can take longer if additional information is required.

Therefore, while I cannot provide an exact date for Apotex's Ruxolitinib FDA submission, I can confirm that the drug was approved by the FDA in November 2011.

Sources:

1. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ruxolitinib)